Hemophilia Treatment Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

HEMOPHILIA TREATMENT MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027

REPORT DESCRIPTION Hemophilia Treatment Market - Overview Global Hemophilia Treatment Market, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 11,474.3 million in 2018, and is expected to exhibit a CAGR of 5.9%, over the forecast period (2019-2027). For instance, according to the World Federation of Hemophilia (WFH), around 440,000 people across the globe were suffering from hemophilia, out of which around 173,000 people were diagnosed with hemophilia A or B in 2017. Major players are focused on product launches and approvals owing to the rising demand for hemophilia treatment. For instance, in March 2016, the U.S. Food and Drug Administration approved Kedrion’s Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial, for treatment of factor VIII deficiency. Moreover, in May 2018, Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche Group launched its anticoagulation factor IXa/X humanized biospecific monoclonal antibody/coagulation factor VIII substitute, HEMLIBRA, for routine prophylaxis, to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors. Browse Research Reports: https://www.coherentmarketinsights.com/marketinsight/hemophilia-treatment-market-2012 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Browse 35 Market Data Tables and 21 Figures spread through 188 Pages and in-depth TOC on 'Hemophilia Treatment Market’- global forecast to 2027, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)' Asia Pacific is expected to offer lucrative growth opportunities for players operating in the hemophilia treatment market owing to the favorable regulatory scenario and guidelines by government authorities, which, in turn, is expected to fuel growth of the market over the forecast period. For instance, according to the World Hemophilia Foundation’s 2015 report of National Tenders for Purchase of Clotting Factor Concentrates, According to the Chinese Ministry of Health report 2012, in China, outpatient hemophilia treatment is covered by health insurance schemes in more than 80% of the cities in China, with reimbursement caps and patient co-pay requirements more than 50%. Moreover, annual reimbursement is usually capped below US$ 16,000. Moreover, several major players in the market are focusing on collaborations with the aim of developing novel therapies for factor VIII deficiency treatment, which is expected to facilitate growth of the market over the forecast period. For instance, in August 2018, RCSI, a Dublin-based international health sciences institution, and Bayer AG entered a research collaboration to develop new treatment options for people with severe hemophilia. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2012 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Key Takeaways of the Hemophilia Treatment Market: The global hemophilia treatment market is expected to exhibit a CAGR of 5.9% over the forecast period owing to rising incidence of hemophilia, and approvals and launch of novel products. For instance, according to the National Hemophilia Foundation’s 2018 report, globally one in 10,000 people are born with hemophilia A due to deficiency of clotting factor VIII, and one in 50,000 people are born with hemophilia B due to lack of clotting factor IX. Among product type, the plasma derived coagulation factor concentrates segment held a dominant position in the hemophilia treatment market in 2018 owing to cost effectiveness. For instance, according to the reports published by the World Federation of Hemophilia in 2016, the demand for plasma derived coagulation factors is high compared to recombinant coagulation concentrates due to their affordability and easy availability in emerging economies.

Companies operating in the global hemophilia treatment market include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, F. Hoffmann-La Roche AG.

ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.

SERVICES INDUSTRY ANALYSIS

CUSTOMIZED RESEARCH

SYNDICATED RESEARCH

MARKET INTELLIGENCE SERVICES

CONSULT STUDIES

COUNTRY SPECIFIC STUDIES

ABOUT CMI SECTOR COVERAGE

BIOTECHNOLOGY

CLINICAL DIAGNOSTIC

HEALTHCARE IT

MEDICAL DEVICES

MEDICAL IMAGING

PHARMACEUTICAL

OUR CLIENTS

 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators

 Private and Government organization

 Distributors, Retailors and Value Added Resellers

 Outsourcing Companies

 Healthcare IT Solutions Developers

 Universities and Business Schools.

KEY STATS

RESEARCH SOLUTIONS

100+

FEASIBILITY STUDIES

Insights Published Per Year

GLOBAL REPORTS

150+

Consulting Projects Till Date

COUNTRY ANALYSIS CONSULT PROJECTS

125+

Clients Worldwide Per Year

110+

SURVEY RESEARCH

EXCEL FORECAST DATABASE

CUSTOMIZED SOLUTIONS

COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS

Analysts and Contract Consultants

Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702

Turn static files into dynamic content formats.

Create a flipbook